Articles On Monash IVF Group (ASX:MVF)
Title | Source | Codes | Date |
---|---|---|---|
Why this sold-off ASX healthcare share could be an exciting dividend buy
The ASX healthcare share Monash IVF Group Ltd (ASX: MVF) could be an underrated ASX dividend share, in my eyes. If we look at the chart below, we can see that Monash IVF briefly touched a 52-week low of $1.11 yesterday. In the last... |
Motley Fool | MVF | 4 days ago |
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | MVF | 2 weeks ago |
Health Check: Control Bionics eyes 20pc revenue growth and ‘near term’ profitability
Control Bionics says it has overcome the “challenges” of the 2023-24 year Ord Minnett identifies the health sector stunners Noxopharm finds a drug manufacturer to kick-start its lupus trial Health Check is renowned biotech journo Tim Bo... |
Stockhead | MVF | 1 month ago |
Sydney data centre designer Greenbox Architecture acquired by US multinational Woolpert
Greenbox Architecture, a full-service firm that has worked on the likes of Monash IVF's (ASX: MVF) flagship facility and NEXTDC's (ASX: NXT) most recently built Sydney data centre, has been acquired by US-headquartered Woolpert for an undis... |
businessnewsaustralia.com | MVF | 1 month ago |
Scott Power: This sleep devices maker is dreaming big with its 2030 strategy
ResMed unveils its 2030 strategy with revenue expected to grow in high single digits for the next five years With a weaker share price Power said Monash IVF could provide a buying opportunity ahead of its AGM in November ASX health stocks... |
Stockhead | MVF | 1 month ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | MVF | 1 month ago |
Why Challenger, Coronado Global, Monash IVF, and Woodside shares are tumbling today
The S&P/ASX 200 Index (ASX: XJO) is having a better day on Thursday. In afternoon trade, the benchmark index is up 0.2% to 7,965.5 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's why... |
Motley Fool | MVF | 2 months ago |
ScoPo’s Powerplays: ASX health stocks rise but are ‘lacking any momentum’
ASX health stocks rise at time of publishing, in line with broader markets amid mixed reporting season EBOS FY24 result in line with consensus as it looks to fill hole by loss of Chemist Warehouse contract Healius says pathology needs more... |
Stockhead | MVF | 3 months ago |
ASX Market Close: Bourse rises on the back of high performing IT sector | August 22, 2024
The ASX200 has once again closed higher, up 0.21% at 8,027 points. The IT sector was the strongest performer up 1.9%, followed by Industrials 1.3% and Real Estate 0.8%. Utilities was the poorest performer and finished the day around a... |
themarketonline.com.au | MVF | 3 months ago |
This high-performing ASX All Ords stock just crashed 12% on its earnings results. Here's why
The All Ordinaries Index (ASX: XAO) is up 0.4% in early afternoon trade, but it's not getting any help from this crashing ASX All Ords stock. The company in question is Monash IVF Group Ltd (ASX: MVF). Before market open this mornin... |
Motley Fool | MVF | 3 months ago |
ASX Set to Rise as US Stocks Surge on Growing Rate Cut Prospects
Australian shares are set to rise as US stocks gained in afternoon trade, buoyed by revisions to jobs data that largely met expectations. This development reinforces the view that the US labor market is cooling, increasing the likelihood th... |
Kalkine Media | MVF | 3 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | MVF | 3 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | MVF | 3 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | MVF | 4 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | MVF | 6 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | MVF | 6 months ago |
7 ASX All Ords shares smashing new 52-week highs on Tuesday
It's looking like this Tuesday will be another positive day for the Australian share market and most ASX All Ords shares. At the time of writing, the All Ordinaries Index (ASX: XAO) has risen by a healthy 0.4%, leaving the index at just ove... |
Motley Fool | MVF | 7 months ago |
Fed comments & oil rally trigger afternoon sell off
US markets opened in positive territory before Fed rates commentary and a pop in oil prices spooked traders and triggered an afternoon sell off. The Dow Jones finished the day down 1.4 per cent, the S&P500 closed down 1.2 per cent aft... |
ShareCafe | MVF | 7 months ago |
Closing Bell: ASX dragged down by ex-divvy stocks as banks take lead; Gold’s rally relentless
The ASX 200 lifted modestly by +0.2% on Thursday as gains in Tech and Industrial stocks were offset by losses in Energy. Local traders brushed out dovish comments from Fed Chair Jerome Powell last night. Appearing before Congress, Powell r... |
Stockhead | MVF | 8 months ago |
S&P 500 gains following Powell’s comments
The S&P 500 rose Wednesday as investors attempted to turn a corner following back-to-back losing sessions on Wall Street. The S&P 500 added 0.51 per cent to 5,104.76, while the Nasdaq Composite gained 0.58 per cent to 16,031.54. T... |
ShareCafe | MVF | 8 months ago |
S&P 500 gains as investors navigate tech slump
Note: Figures recorded at 7:40am AEDT. Updated figures and a video recording will be available at 9am AEDT. The S&P 500 rose Wednesday as investors attempted to turn a corner following back-to-back losing sessions on Wall Street. The br... |
ShareCafe | MVF | 8 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | MVF | 8 months ago |
ASX Rebalance: Tech in, lithium out of S&P/ASX 200 as uranium stocks enter S&P/ASX 300
QBE Insurance elevated to S&P/ASX 20 as gold miner Newmont removed Flight Centre and Pro Medicus both make the S&P/ASX 100 in March rebalance Several tech companies make benchmark S&P/ASX 200 but not so good for resources Mar... |
Stockhead | MVF | 8 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | MVF | 8 months ago |
Best calls to action – Monday, 26 February 2024
Today, Monday the 26th of February 2024, we are happy to buy Wagners (ASX:WGN), Bapcor Limited (ASX:BAP), Super Retail Group (ASX:SUL), Cedar Woods Properties (ASX:CWP), Accent Group (ASX:AX1), Avita Medical (ASX:AVH), Jumbo Interactive (AS... |
Morgans | MVF | 8 months ago |
ASX Large Caps: AI craze sweeps ASX; Block Inc, Aussie Broadband up 17pc, Newmont dips 7pc
ASX gains on Nvidia-fuelled rally AI adjacent stocks, such as data centre companies, also surge Afterpay parent Block Inc surges 17pc, Newmont crashes 7pc The ASX 200 gained around 0.4% as the AI craze swept through global stock markets... |
Stockhead | MVF | 9 months ago |
ScoPo’s Powerplays: ASX health stocks flat in ‘up and down’ reporting season
ASX health sector flat for week as broader market falls during volatile reporting season Avita Medical reports strong full year FY23 results, forecast to reach cashflow breakeven in FY25 Clinuvel Pharmaceutical H1 FY24 results below consen... |
Stockhead | MVF | 9 months ago |
ScoPo’s Powerplays: ASX health stocks tumble as CSL bleeds after Phase III trial misses endpoint
ASX health sector falls broader market with some key names ailing in reporting season CSL Phase III trial fails to meet primary efficacy endpoint but delivers solid H1 FY24 results Neuren Pharmaceuticals falls 13% on Friday after short sel... |
Stockhead | MVF | 9 months ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | MVF | 1 year ago |
2 ASX small-cap shares I'd buy for growth AND dividends
ASX small-cap shares can be a great area of the share market to find little-known opportunities that could deliver strong long-term returns in the form of both dividends and capital growth. Big businesses like Commonwealth Bank of Australi... |
Motley Fool | MVF | 1 year ago |
US stocks close higher amid falling Treasury yields
US stocks rose Tuesday, boosted by declines in Treasury yields as Wall Street assessed the geopolitical risks from the Israel-Hamas war. The benchmark 10-year Treasury yield fell nearly 13 basis points to about 4.65 per cent, as investors... |
ShareCafe | MVF | 1 year ago |
ASX Escrow Watch: Which lithium and resources companies are releasing shares?
Voltaic Strategic Resources to release more than 31 million fully paid ordinary shares Besra Gold to release more than 51 million CDIs in escrow since the company listed Fertility company Monash IVF to release around 500,000 fully paid ord... |
Stockhead | MVF | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | MVF | 1 year ago |
6 ASX All Ords sharing cracking new 52-week highs on Tuesday
This Tuesday's trading session has been a pretty depressing one for the All Ordinaries Index (ASX: XAO) and most ASX All Ords shares. At present, the All Ords has lost a notable 0.42% and is back under 7,400 points. But there are a few ASX... |
Motley Fool | MVF | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | MVF | 1 year ago |
Market Highlights: ASX to open higher, Tesla jumps 10pc, and 5 ASX small caps to watch
The ASX is set to open higher on Tuesday It was all about Tesla on Wall Street overnight, as the stock jumps 10pc Morgan Stanley says healthcare stocks are undervalued Australian shares are set to open higher on Tuesday after a rally on... |
Stockhead | MVF | 1 year ago |
Major US indexes fall as Fed rate hike fears return
Stocks sold off Wednesday, continuing the sluggish start to September, as concerns mounted that the Federal Reserve may not be done hiking interest rates. The Dow Jones Industrial Average sank 198.78 points, or 0.57 per cent, to end at 34... |
ShareCafe | MVF | 1 year ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | MVF | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | MVF | 1 year ago |
ScoPo’s Powerplays: CSL leads ASX health stocks down is reporting season; ‘we weren’t expecting that’
ASX health sector falls in mixed week of FY23 results as reporting season continues Monash IVF reports solid FY23 result and forecasts higher IVF cycles going forward Ramsay healthcare plunges on disappointing FY23 result and cut in final... |
Stockhead | MVF | 1 year ago |
Monash IVF: Cycling along nicely
Monash IVF's (ASX:MVF) FY23 was in line with guidance of underlying NPAT of $25.5m (up 14.%). |
Morgans | MVF | 1 year ago |
Best calls to action – Wednesday, 23 August 2023
Today, Wednesday the 23rd of August, we are happy to buy BHP Group (ASX:BHP), Data#3 Limited (ASX:DTL), Objective Corporation (ASX:OCL), and Monash IVF (ASX:MVF). |
Morgans | MVF | 1 year ago |
ScoPo’s Powerplays: CSL, Cochlear drag ASX health sector up in mixed start to reporting season
ASX health sector outperforming the broader market but remain flattish for week CSL reports solid FY23 results after record plasma collections and lift in sales Cochlear FY23 sales revenue increases 19% on pcp to a record $1.956 billion... |
Stockhead | MVF | 1 year ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | MVF | 1 year ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | MVF | 1 year ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | MVF | 1 year ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | MVF | 1 year ago |
ASX Escrow Watch: Lithium plays and health companies due to release shares
Pilbara Minerals to release shares issued under its NED fee sacrifice offer Imricor Medical Systems to release ~75k shares of Class A common stock Monash IVF Group to release more than 135,000 shares in mid June Escrow Watch is Stockhea... |
Stockhead | MVF | 1 year ago |
Trading Places: Beer giant Kirin wants to cure your hangover too, snapping up Blackmores for $1.2bn
Japanese beer giant Kirin becomes substantial shareholder of Blackmores after $1.2 takeover bid State Street Corporation becomes substantial shareholder of Gold Road Resources as gold prices rallies State Street Corporation sells out of Sa... |
Stockhead | MVF | 1 year ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | MVF | 1 year ago |